What the component literature reports on KLOW peptide dosage — by species, by route, by arm

In plain English

There is no validated human dose for KLOW peptide. There is no FDA-approved dosing protocol, no clinical-trial dose-finding study and no pharmacopeial standard for the four-peptide blend. What exists is a canonical research-vial composition — most commonly listed as 80 mg total, with the four components at fixed mass ratios — and a body of single-component preclinical literature where each peptide was administered to cells or animals at doses that cannot be extrapolated directly into a human dosing recommendation. This page summarizes that research context, not a dosing guide. No instruction to take a specific dose appears here; none should be inferred. The blend also carries an inherent pharmacokinetic mismatch — the four components clear the body at markedly different speeds — which means a single vial cannot deliver all four at matched, sustained exposures. That structural limitation is described in the final section and belongs at the front of any serious reading of the KLOW dosage question.

KLOW peptide dosage

The canonical research-vial KLOW peptide dosage context is an 80 mg total vial, composed as follows: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. No validated human dosing exists for the blend; component-level research doses differ widely by species and route and are not additive into a single 'KLOW dose.'

The lyophilized blend is reconstituted with bacteriostatic water for laboratory handling. Reconstituted solution is typically refrigerated. Copper(II) in GHK-Cu can participate in redox chemistry — a theoretical compatibility consideration when co-dissolved with the other peptides — and this has not been formally characterized for the KLOW mixture.

KLOW dosage

The component-level research doses extracted from the published literature are as follows.

For the KPV arm: 10 nM in cell culture (Caco2-BBE and HT29-Cl.19A intestinal cells) and Jurkat T cells; 100 µM in drinking water for C57BL/6 colitis mice ^[3]. The 2024 KPV/FK506 nanodrug study did not specify an absolute dose per animal ^[8].

For the GHK-Cu arm: nanomolar concentrations (1–10 nM) in fibroblast cell culture for the gene-expression studies ^[5]; topical formulations in human cosmetic clinical studies ^[4]. The plasma reference range is approximately 200 ng/mL at age 20, declining to approximately 80 ng/mL by age 60 — a natural aging correlation, not a therapeutic target.

For the BPC-157 arm: intraperitoneal doses of 10 µg, 10 ng or 10 pg per rat in the Achilles tendon transection model ^[2]. The 2025 IV human pilot used 10 mg on day one and 20 mg on day two in 250 cc saline as a one-hour infusion ^[6] — tiny n (n=2) and not an efficacy or dose-finding trial.

For the TB-500 arm: based on the full-length thymosin beta-4 literature — topical application and intraperitoneal administration in rat wound models; as little as 10 pg stimulated keratinocyte migration 2–3-fold in vitro ^[1]. These doses are for the native 43-amino-acid protein, not the short TB-500 fragment.

KLOW peptide dosage and frequency

No published study has established a dosage and frequency schedule for the four-peptide KLOW blend. The component literatures used different routes, species, doses and schedules that cannot be merged into a unified human protocol. The BPC-157 Achilles tendon studies used once-daily intraperitoneal administration; the GHK-Cu studies used topical application; the KPV colitis studies used oral delivery in drinking water; the TB-500 thymosin beta-4 studies used topical and intraperitoneal routes. These are four different route-and-schedule contexts. No pharmacokinetic modeling has been published for the co-formulated blend, and no frequency recommendation follows from the existing component literature.

This site does not provide dosage recommendations for any compound.

The pharmacokinetic mismatch

The KLOW blend carries an inherent pharmacokinetic (the study of how a substance is absorbed, distributed, metabolized and eliminated — how it moves through the body over time) mismatch. The four peptides have markedly different reported half-lives — the tripeptides KPV and GHK-Cu clear far faster than the larger BPC-157, and the TB-500 fragment differs from native thymosin beta-4 — producing a mismatch within a single co-formulated vial. A single dose cannot hold all four components at matched exposures over time.

This is not a criticism specific to KLOW. Any multi-component co-formulation whose constituents differ in clearance rates faces this structure. It is mentioned here because it is a structural fact that constrains the combination rationale: the mechanistic argument for combining these four peptides is strongest if all four are present simultaneously in the target tissue, but the pharmacokinetics make that condition difficult to achieve from a single vial dose. No pharmacokinetic study of the KLOW blend has been published.